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Effective therapeutic vaccines contain two primary constituents, antigen and adjuvant. Adjuvants
consisting of microbial pattern molecules play a central role in vaccination. Successful vaccine requires
efficient induction of antibody (Ab), type I interferons (IFN), cytokines/chemokines, cytotoxic T
lymphocytes (CTL) and/or NK cells. Toll-like receptors (TLRs) in myeloid dendritic cells (mDC)
essentially act as adjuvant receptors and sustain the molecular basis of adjuvant activity. Current con-
sensus is that TLRs and their adapters introduce signals to preferentially induce IFN-a/b, chemokines
and proinflammatory cytokines, and mature mDC to augment antigen presentation. Although most of
these data were obtained with mice, the results are presumed to be adaptable to humans. Whenever
TLR pathway is activated in mDC, NK and/or CTL activation is promoted. For induction of antigen-
specific CTL toward phagocytosed material, cross-priming must be induced in mDC, which is also
sustained by TLR signaling in mDC. Since the TLR responses vary with different adjuvants, mDC func-
tions are skewed depending on adjuvant-specific direction of mDC maturation. It appears that the direc-
ted maturation of mDC largely relies on selection of appropriate sets of TLRs and their adapter signaling
pathways. Synthetic chimera molecules consisting of TLR agonists and target antigens are found to be
effective in induction of CTL to eliminate target cells in vivo. Here, we review the role of human
TLRs and adapters in a variety of host immune responses. We will also describe the relevance of
adjuvants in the manipulation of receptors and adapters in vaccine therapy.
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Adjuvants as ligands for TLRs
Microbial pattern molecules with a high potential for host
immune activation have been classified into adjuvant. Adjuv-
ant activity has been found in a variety of infectious microbes
and endogenous material of host origin. Freund’s complete
adjuvant (FCA) consisting of dead mycobacteria conjugated
with mineral oil augments vaccine response, i.e. antibody
(Ab) production, CTL induction and NK activation (1,2).
Without the adjuvant, usually only a poor immune response
is observed upon vaccination. Thus, the adjuvant has been an
essential factor for provoking strong host immune responses.
It has been elucidated that myeloid dendritic cells (mDCs), a
representative cell population of antigen-presenting cells, and
plasmacytoid dendritic cells (pDCs), formerly called type I
interferon (IFN)-producing cells, are the targets for most of
the adjuvants (3). In this context, Janeway and Medzhitov (4)
suggested that dendritic cells (DCs) express two sorts of
receptors, antigen (Ag) uptake receptors for Ag-presentation
by MHC and receptors for microbial pattern molecules, that
are receptors for adjuvants. Both Ags and adjuvant pattern
molecules are derived from microbes and differentially act
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lymphocyte activation.
The molecular basis of the adjuvant function was poorly
delineated until adjuvant receptors were identified. The most
common question in this regard is ‘what is the receptor for
adjuvant pattern molecules?’ In 1997, Medzhitov et al. (5)
characterized a human homolog of drosophila Toll (described
by J. A. Hoffmann in 1996) (6), later named TLR4. They first
predicted its function to be the augmentation of immune
response (4,5). Currently, TLR is identified as a family of
receptors consisting of >10 protein members both in humans
and mice. In recent years, evidence has been accumulating
that either each TLR dimer or a combination of TLRs serves
as a receptor complex for the recognition of a specific micro-
bial pattern molecule (3,7). The recognition is then fol-
lowed by TLR-specific signaling and corresponding cellular
immune response (Table 1). Thus, the TLR family of proteins
serves as signaling receptors crucial for augmenting immune
response. It is notable that most of the TLR proteins reside in
DCs. Although some TLRs are present on T, B, NK cells and
epithelial cells and recent studies suggest the importance of
TLR on these cells for primary antiviral response (8), their
functions remain largely unknown. The possible immune
responses and effectors induced by mDC are discussed below.
Role of TLRS in DCs
mDCs are central to T/B cell activation (9,10). They facilitate
production of Abs through the induction of differentiation of
B lymphocytes. T lymphocytes are differentiated by matured
mDCs into T helper I (Th1), Th2 and CTL. mDCs catch up
antigens, alter the functions and migrate to draining lymph-
nodes (Fig. 1). When antigen and adjuvancy coincidently
stimulate mDC maturity, antigenic peptide presentation on
MHC is augmented. Upregulation of co-stimulatory and
MHC molecules, expression of chemokine receptors, presenta-
tion of antigens, secretion of cytokines and chemokines are
accelerated by adjuvants in mDC (7,9,10). TLRs on mDCs
are involved in these pivotal events leading to lymphocyte
activation (Fig. 1). Regulatory T cell (Treg) function is sup-
pressed by IL-6, which is produced by mDC in response to
TLR activation (11). NK and NKT cells are activated in
response to TLR-mediated mDC maturation (12). Memory
cell formation may be imparted by mDC depending on its
maturation properties, which are competent to lymphocyte
Table 1. Human TLRs and their adapters
huTLR Amino
acids
mAb Adapters Ligands DC
subsets
Modes
TLR1 786 TLR1.136 M-1/M-2 triacyl BLP M NF-kB
TLR2 784 TLR2.45 M-1/M-2 PGN, BLP M NF-kB
TLR3 904 TLR3.7 T-1 (M-1) dsRNA M NF-kB/IRF-3
TLR4 839 HTA125 M-1/M-2 LPS, Taxol M NF-kB/IRF-3
RSV-F
TLR5 858 — M-1 flagellin M NF-kB
TLR6 796 TLR6.127 M-1/M-2 diacyl BLP M NF-kB
TLR7 1049 TLR7.360 M-1 ssRNA P NF-kB/IRF-7
TLR8 1059 TLR8.90 M-1? ssRNA M NF-kB/IRF-7
TLR9 1032 — M-1 CpG DNA P NF-kB/IRF-7
M-1, MyD88; M-2, Mal/TIRAP; T-1, TICAM-1/TRIF; T-2, TICAM-2/
TRAM. TLR1, TLR6 and TLR10 are members of the TLR2 subfamily and
together with TLR2 recognize different sets of microbial pattern molecules
and support activation of TLR2. Mice do not have TLR8, but possess a protein
which resembles TLR7 in its structure and function. Further, their distribution
is also different. Functional modes of each adapter were identified as ‘M’ and
‘T’ types. M, MyD88-dependent pathway; T, TICAM-1-dependent pathway.
In DCs subsets, M is myeloid DCs while P is plasmacytoid DCs. ‘Modes’
represent transcription factors activated by each TLR.
Figure 1. Role of human TLRs in mDC maturation followed by activation of various lymphocytes. Immature dendritic cells (mDC) residing in local tissue
phagocytose exogenous antigen (Ag) and pattern molecule (namely adjuant) and initiate the maturation process. During maturation mDC induce IFNs, cytokines
and chemokines, allow the upregulation of co-stimulators, NK-activating ligands (ULBP, MIC, etc) and MHC, and activate a variety of lymphocytes. These
maturation events are largely dependent on adjuvant properties. Also, adjuvant may participate in switching on of some unknown mechanisms which are essential
in induction of CD8þ CTL by mDCs.
32 Human TLRs in vaccine therapyproliferation, and be established in conjunction with TLR sig-
naling in mDCs. Exogenously-added antigens that are not
expected to gain access to the cytoplasm of mDCs are presen-
ted on MHC class I molecules by a process called cross-
priming. TLR signaling also promotes cross-priming in
mDC, which potently induces MHC class I-restricted CTL
against phagocytosed antigens (13). This TLR-driven cross-
priming will be discussed more in the later sections. Simultan-
eous stimulation of DC by microbial patterns and antigens
induces robust immune activation. It is notable that DC sub-
sets have distinct receptor-expression profiles which enable
them to respond to specific types of pathogens (7,14). In addi-
tion, mDCs express pattern-recognition receptors other than
TLRs inside the cells (15). Furthermore, there are a number
of microbe-specific phagocytic receptors in mDC, which
include lectins, Ig superfamily and complement receptors.
Functional assignment of TLRs and these intracellular and
phagocytic receptors in mDC are important to depict the DC
pattern recognition system. Elucidation of the kind of TLRs
and their combinations that are mainly responsible for each
immune response is to be further resolved.
The distribution of TLR expression in
DC subsets
TLR1, 2, 4, 5 and 6 are members of a TLR subfamily which
recognizes microbial constituents that are absent in human
cells (Table 1). These TLR subfamily members reside on the
cell surface. Human mDCs, but not pDCs express these TLR
subfamily members (14). Human mDCs also express TLR3
and TLR8 while pDCs express TLR7 and TLR9. These four
TLRs preferentially recognize microbe-specific modifications
of nucleotide sequences and are localized in certain endo-
somes inside the cells (14,16). Unlike mouse mDCs, human
mDCs do not express TLR9. Current consensus is that TLR3,
7, 8 and 9 are proteins of TLR subfamily participating in the
recognition of nucleic acid derivatives of viruses and bacteria
(Table 1). In mice, mDCs express functional TLR3 and
TLR9 inside the cell, while TLR8 remains dysfunctional
(16). Mouse pDC expresses TLR7 and TLR9 similar to human.
These differences between mouse and human DC subsets may
preclude us from simple extrapolation of mouse TLR func-
tions in mouse DCs to the human system. Typical human
pDC phenotype is CD11C
 /CD4
þ with BDCA4þ, while that
of mouse pDC is CD11C
þ/CD11B
 /GR
 1þ/B220 (16).
Thus, mouse and human also differ in the pDC phenotype.
Since we mainly focus on antigen-presenting ability of mDC
in the context with TLR adjuvancy, the pDC story (see other
references) is largely omitted in this review.
Functions of the adapters
So far, four adaptors, MyD88, Mal/TIRAP, TICAM-1 (TRIF)
and TICAM-2 (TRAM), have been identified in human and
mouse cells (17–19). These adapters exclusively contain the
TIR domain (Fig. 3). We have investigated the functions of
adapters and found that stimulation of mDC with individual
pattern molecules is largely transduced by different sets of
adapters resulting in distinct outputs. TLR subfamily
expressed on cell surface mainly engages in NF-kB activation
through the adapter molecule MyD88 (17) (Fig. 2). TLR4 is
the only exception in that it activates both NF-kB and IRF-3.
In contrast, the nucleic acid-recognizing TLRs, TLR3, 7 and
9 activate the IFN promoter (Fig. 2). The properties of
these adapters related to the activation of mDC (i.e. antigen-
presenting cell) may be summarized as follows: MyD88 is
engaged in the activation of NF-kB and p38 MAPK (17), but
has no ability to induce type 1 IFN in mDCs. An alternatively
spliced form of MyD88 may regulate the MyD88 adapter
activity. Mal/TIRAP bridges the TIR domain of TLR2/4 and
MyD88 (18,19). Mal/TIRAP itself exhibits weak NF-kB
activation activity. The Mal/TIRAP function may be
modulated by proteolysis.
TICAM-1 preferentially activates the IFN-b promoter via
dimerization of IRF-3 in mDC (20), which explains part of
the ‘MyD88-independent’ pathway. TICAM-1 has ability to
activate NF-kB also. The TICAM-1-mediated NF-kB activa-
tion is supported by RIP1 which binds the C-terminus of
TICAM-1 (21). However, TICAM-1-dependent IRF-3 activa-
tion is made by the NAP1/TBK1/IKKe complex (22) that
binds to the N-terminus of TICAM-1. Particularly if it
is of viral, TICAM-1 may be susceptible to proteases (23).
TICAM-2 bridges the TIR domain of TLR4 and TICAM-1
(18,19). Its ability to activate IRF-3 in the absence of
TICAM-1 is minimal, if any. Its acylation permits the mole-
cule to anchor on the inner leaflet of membrane. Hence, the
two effective adaptors, MyD88 and TICAM-1, and two brid-
ging adaptors, Mal/TIRAP and TICAM-2 exist in DCs (Fig. 3).
TLR3 activates IRF-3 and IFN-b promoter through the
adapter TICAM-1, whereas TLR7 and 9 activate IRF-7 and
IFN-a promoter via MyD88 (24). The distribution of these
TLRs is different: TLR3, TLR8 and surface-expressed TLRs
reside in antigen-presenting mDCs while TLR7 and 9 are
in pDCs in human (Table 2). Thus, the TLR3, TLR8 and
surface-expressed TLRs such as TLR2, 4 and 5 are mainly
involved in the modulation of antigen-presentation in mDC
(Fig. 3).
The functional profile of TLR2 and TLR5 includes
activation of NF-kB (17) but not induction IFN-b, which
matches the functional properties of the adapters they select.
Table 2. Distribution and subcellular localization of human TLRs in DC
DC subsets Monoclonal Abs against
TLR1 TLR2 TLR6 TLR4 TLR5 TLR3 TLR7 TLR8 TLR9
Monocyte-
derived
þþ þ þþþ(þþ)   (þþ)  
Plasmacytoid       (þþ)   (þþ)
(þþ) TLRs with nucleotide-recognition properties (TLR3, 7, 8. 9) reside in
endosomes.
þ TLRs (TLR1, 2, 4, 5, 6) are expressed on cell surface to recognize microbial
patterns.
eCAM 2006;3(1) 33dsRNA-mediated TLR3 activation predominantly induces
IFN-b, reflecting the function of the adapter TICAM-1
(18,19). LPS-TLR4 complex activates both NF-kB and the
IFN-b promoter, consistent with the fact that TLR4 recruits
both MyD88 and TICAM-1 in an indirect manner. Thus, sets
of adapters selected by each TLR appear to be crucial for
relevant adjuvant function.
Manipulation of TLR system for
adjuvant vaccine therapy
Functions of antigen-presenting mDC can be controlled at
three points in the TLR cascade. Property of the adjuvant
is the first to regulate TLR-mediated maturation of mDC.
Secondly, modulation of TLR activity occurs by the addition
Figure 2. Association betweenhumanTLRsand adaptorsdetermineeach TLR-specific signalingpathway.Topologyof theadaptorproteinsinthe TIR domainsof
TLR2, TLR3 and TLR4 is shown in the schema. The complex consisting of each TIR and adaptors delivers TLR signaling to activate NF-kB and the IFN-b
promoter (IRF-3). In pDC, activation of TLR7 or 9 happens to activate IRF-7 in a MyD88-dependent way followed by induction of IFN-a. Representative
ligands of TLRs are shown on the top.
Figure 3. TLR adapters and possible signals induced in human DCs. MyD88 and TICAM-1 are functional adapters that activate both NF-kB and type I IFN pro-
moters. Important downstream molecules currently identified are shown in the figure. Plasmacytoid DC (pDC) predominantly expresses TLR7 and TLR9 which
recognize nucleotide derivatives. MyD88 activates IRF-7 in pDCs. Activation of different pathways is elicited in mDC.
34 Human TLRs in vaccine therapyof soluble forms of TLRs or TLR-blocking molecules. Finally,
TLR signaling can be positively regulated by the adapters or
negatively regulated by their inhibitors. Recent finding sug-
gests that there are small synthetic molecules that block
TLR-adapter interaction (25). More information about TLR
agonists in association with adjuvants was recently published
(26). Examples for the second and third control steps are as
follows.
Alternatively spliced forms of TLR2, TLR4 and probably
TLR3 appear to serve as dominant-negatives to block the
relevant TLR activation in response to their ligands (27–29).
Reports on this type of TLR regulation were published in
human and mouse TLRs (27–29). Fish has a gene encoding a
soluble TLR5, which acts as an amplifier of the flagellin-
mediated membrane TLR5 signaling that induces acute phase
cytokines as well as soluble TLR5 (30). Although human
has no gene for soluble TLR5, the amplification of flagellin
signal by soluble TLR5 may be conserved. Fish soluble
TLR5 can physiologically bind flagellin and augment the
functions of human membrane TLR5 in response to flagellin.
The results may offer an adjuvant positively regulating
flagellin response in human mDCs (31). Lipopolysaccharide-
binding protein or soluble CD14 may upregulate LPS-
mediated TLR4 activation (32). It is likely that yet to be
identified catch-up receptors for pattern molecules function
as TLR modulators. Antagonists of TLRs either binding to
the LRR or TIR domains of each TLR will be applicable for
patients with inflammation or autoimmune status to block off
TLR activity.
In the human kidney cell line HEK293 cells, overexpressed
adapters enhance activation of corresponding pathways lead-
ing to the promoter activation even in the absence of adju-
vant (22). Similarly, overexpressd dominant-negative forms
of adapters effectively block the downstream signaling of
adapters (22). In mDCs, adapter function can be positively
regulated by the transfection of correspondingly associated
adapters.
Cross-priming induced by TLR stimuli in MDC
TLRs and other receptors in mDC increase antigen-presenting
ability by maturing mDC. However, the molecular mechanism
whereby the TLRs and adaptors are potentially involved in
antigen-presentation by mDC has not yet been characterized.
Cross-priming is an essential functional feature for vaccines
to induce CTL from CD8 T cells. Here, we mention a crucial
function of TLR, cross-priming, in terms of TLR2/4 and
TLR3. Although human TLR8 in mDC may participate in
cross-priming, it remains unestablished. Effective CTL induc-
tion is observed secondary to TLR2/4 and MyD88-dependent
mDC maturation if appropriate exogenous Ag is simultan-
eously supplemented in a study that used gene-knockout
mice (33). Acylated devivatives of muramyl dipeptide (MDP)
of BCG-cell wall skeleton (CWS) acts as TLR2/4 agonist to
selectively activate the MyD88 pathway (34). Cytokines
and chemokines are effectively induced in mDCs by combined
activation of TLR2/4 by BCG-CWS leading to cross-priming-
competent mDC followed by CTL induction (33). The CTL
induction by BCG-CWS-primed mDCs does not occur in
MyD88-knockout mice and mDCs from them exerted almost
no ability to proliferate CD8 T cells in vitro. Thus, it appears
that there is a TLR-signal pathway which engages MyD88 to
induce cross-priming in mDC. The outline of this pathway is
shown in Fig. 4 and more precisely in Fig. 5. Some unknown
molecules involved in this pathway may participate in cross-
priming of exogenously-added antigen in mDC.
dsRNA is a TLR3 agonist that activates TLR3-TICAM-1
pathway (35). The outline of this pathway is shown in Fig. 4
and with molecular interaction in Fig. 5. TLR3 signaling is
also important in eliciting cross-priming leading to induction
of MHC class I presentation and CTL induction in response
to exogenously-added antigens (36). In light of this observa-
tion, multiple TLR pathways must be involved in cross-
priming in mDCs. These events may be generalized for most
human infections and cancers where mDCs sense TLR agon-
ists and antigens from target cells. Taken together, to induce
systemic activation of CTL, supplementation of TLR agonists
or adapters to the vaccine adjuvant appears effective, particu-
larly if pathogens lack agonistic activity to TLR2/4 or TLR3.
Vaccine adjuvant activity of
TLR for NK activation
NK can be activated by type 1 IFNs and/or instructive
cytokines, IL-12, IL-23 and IL-18 (Fig. 1) (12). TLR3 engages
in NK activation via TICAM-1-mediated signaling in mDCs
(2). Thus, NK can be activated by mDCs that are pretreated
with TLR3 agonist such as dsRNA. This means that mDC
turns an activator for NK if appropriate TLR agonists are pro-
vided (Fig. 4). In light of this, it appears that supplementing
vaccine adjuvant with TLR3 to induce systemic activation
of NK appears to be effective in patients with cancer or
infectious diseases.
If one can supplement the adjuvant cocktail sufficiently
to activate both CTL and NK, it would be possible to eliminate
both MHC-positive and -negative target cells. Although such a
scenario is largely extended from the mouse studies, the same
mechanism of induction of antiviral immunity appears to be
the case in humans according to in vitro studies using human
mDC (7,8,14). Viral infection often induces promotion or
suppressionofDC maturation. SupplementofTLR2/4agonists
to viral dsRNA may relieve the maturation stages of DCs.
MyD88 is the adapter shared by receptors for IL-1b, IL-18
and most members of the TLR family (17). In mDCs, the tran-
scription factor NF-kB is activated in the MyD88 pathway
(17). MyD88 may support events other than those responsible
for innate immune responses and the danger signal induced
by tumors (37,38) or virus-invaded tissue in effecter lympho-
cytes (39,40). In pDCs, the MyD88 pathway also activates
IRF-7 which is followed by robust production of IFN-a (41).
Type I IFN directly enhances the expression of IL-18 R
eCAM 2006;3(1) 35Figure 4. ThetwodistinctTLRpathwaysofmyeloidDCs.NK andCTLareinducedaseffectercells forkillingoftargetssecondaryto activationofTLRsinmDCs
(left panel). Myeloid DCs express TLR2, TLR3 and TLR4, and mature in response to BCG-CWS (TLR2/4 agonist) or dsRNA (TLR3 agonist). In general, TLR2/4
preferentially activates NF-kB via MyD88. TLR3 induces type 1 interferon (IFN). Both CTL and NK are then activated as indicated. In activation of CTL by mDC,
exogenously-added antigen must be presented on MHC class I while the antigen are usually mounts on class II. This, named cross-priming, actually occurs if TLR
signaling simultaneously enters (right panel). Either MyD88 or TICAM-1-mediated signal can induce cross-priming. Although the exact mechanism remains
unknown, many factors are expected to be involved in switch on of cross-priming.
Figure 5. The two signaling pathways of TLR in myeloid DCs. MyD88-dependent pathway are indicated to the left and TICAM-1 pathway are shown to the right
in blue. Many signaling molecules are involved in the two pathways leading to different outputs. NK and CTL are generated by the resultant mDC activation. In
particular, cross-priming must occur in mDC to induce CTL, the molecular mechanism of which are largely unknown.
36 Human TLRs in vaccine therapycomponents (AcPL), IL-1R-related protein (IL-1Rrp) and
MyD88 in NK and T cells (39). This is reminiscent of the
properties of the danger signal in the suppression of tumor
cell progression or viral proliferation (42). It is reasonable to
hypothesize that most danger signals suggest an enhanced
effect of vaccine and activation of adapters. TICAM-1, another
effective adapter, also induces activation of IFN-b and NF-kB
in mDCs (18,19). It does not appear to function in pDCs for
IFN-a induction. TICAM-1 may be an important vaccine
potentiator targeting mDCs. Further studies are needed to
clarify the discerning properties of the two main adapters in
terms of enhancers for vaccine effect.
Application of TLR response for
immune therapy
The development of safe and efficient vaccines for cancer
and infectious diseases remains a major goal in global public
health (43). There are prophylactic and therapeutic vaccines
both of which require two primary constituents, antigen and
adjuvant. Adjuvant may determine the direction of mDC lead-
ing to maturation for CTL induction and/or NK activation for
cellular immune response and Ab production for humoral
immune response. NK activation is a therapeutic feature,
while CTL and Ab induction is useful for both preventive
and therapeutic purpose.
Adjuvant includes a variety of components consisting
of mineral oils, bacterial extracts, viruses and suspensions
of aluminum hydroxide metals. Artificial components were
chemically synthesized with reference to microbial origin,
which were also effective as adjuvants (26,44). In vitro and
animal studies are in progress concerning these materials.
Application of these adjuvants to immune therapies, however,
has not yet clinically explored. This is because augmented
immune response by adjuvants may exacerbate subclinical
autoimmune diseases. In addition, fever and erosion at the
local injected lesion induced by nature of adjuvants some-
times perturb periodical adjuvant administration in patients
(45). Thus, the numbers of adjuvants that are approved and
effective in humans still remain limited.
In the field of immune therapy for cancer, Rosenberg et al.
(46) summarized their elaborate studies on peptide vaccine
therapy for cancer. Only 2.6% of the patients with this therapy
accomplish remission (complete or incomplete). In contrast,
BCG or its component cell wall skeleton has been admin-
istered as adjuvant to patients with colon or lung cancer
(47,48). About 10% of the patient obtained partial remission
and 5 year survival (45,47). The results indicated that there is
no doubt that the sensing of ‘danger’ by the immune system
through recognition of microbial patterns by TLRs and other
receptors has begun to explain the largely empirical field of
vaccine adjuvant biology. It has also spawned a more objec-
tive search and development of compounds with immune
stimulating activity (49). Our perspective is that combination
of peptide and adjuvant would be more effective than either
alone for immune therapy for cancer.
In this context, we have investigated the differential
functional properties of each adjuvant in vitro human mDC
and in vivo mouse studies (40). We particularly focused on
microbial pattern molecules and TLR signal modifiers. We
have examined the use of chimera proteins composed of
small lipopeptides (TLR2 stimulants MALP-2 and Pam 3)
and tumor antigens and found that their potencies to elicit
immune response are greater than those of either alone or
unfused mixture. It has been reported that fused proteins
consisting of TLR agonists and targeted antigens exerts anti-
pathogenic CTL response in vivo in animal studies (50,51).
Thus, we have speculated that fusion molecules consisting of
TLR agonists and tumor antigens would be more effective
for immune therapy for cancer.
TLRs are undoubtedly important in recognition of ‘danger’
molecules generated from self or infectious materials (53).
TLRs are representative adjuvant receptors with sufficient
knowledge on molecular manipulation and control of their
signaling pathways. This is why we summarized this here.
Yet, whether any of the numerous alternative and complement-
ary medicines that claim immune activity contain TLR agon-
ists and promote anti-pathogen immunity or autoimmunity
remains to be established. Further future work on not only
TLRs but also other adjuvant receptors will be needed to offer
each of the adjuvants with differential properties for clinical
use.
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